Regulation, biosynthesis and mode of action of formicamycins, promising new antibiotics with a high barrier to resistanc
Lead Research Organisation:
University of East Anglia
Department Name: Biological Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The formicamycins, and their biosynthetic precursors, the fasmsycins, are produced by the new species Streptomyces formicae, and a single biosynthetic gene cluster (BGC) is responsible for their production. Both groups of compounds are active against MRSA and VRE. Fasamycins bind the active site of FabF and block essential fatty acid biosynthesis to kill Gram-positive bacteria. They also kill Gram-negative bacteria treated with outer membrane permeabilising compounds suggesting they could be modified to enable outer membrane penetration to kill drug resistant Gram-negative pathogens. Formicamycins are even more potent and, importantly, MRSA does not become resistant under laboratory conditions. Despite their linked biosynthesis, fasamycins and formicamycins have very different 3D structures and we propose they have a different cellular target and antibacterial mode of action.
We will determine the regulation of fasamycin/formicamycin production, as well as elucidating the entire biosynthetic pathway. To achieve this, we will utilise CRISPR/Cas9 for genome editing, and ascribe functions to all genes comprising the BGC. This will enable us to produce target compounds at elevated titres for purification and structure elucidation, and for biological activity studies. These will include pathway intermediates and new analogues generated through biosynthetic engineering. Compounds will also be transferred to our collaborator Prof Mike Krische (U of Texas, Austin), a highly experienced synthetic organic chemist specialising in natural products total- and semi-synthesis, who will generate additional derivatives that target Gram-negative bacteria.
Additionally, will identify auto-immunity genes and determine whether the two groups of compounds have different molecular targets and modes of action, and confirm the high barrier to resistance observed for the formicamycins. Such information is critical for the development of any natural product as a potential antibiotic.
We will determine the regulation of fasamycin/formicamycin production, as well as elucidating the entire biosynthetic pathway. To achieve this, we will utilise CRISPR/Cas9 for genome editing, and ascribe functions to all genes comprising the BGC. This will enable us to produce target compounds at elevated titres for purification and structure elucidation, and for biological activity studies. These will include pathway intermediates and new analogues generated through biosynthetic engineering. Compounds will also be transferred to our collaborator Prof Mike Krische (U of Texas, Austin), a highly experienced synthetic organic chemist specialising in natural products total- and semi-synthesis, who will generate additional derivatives that target Gram-negative bacteria.
Additionally, will identify auto-immunity genes and determine whether the two groups of compounds have different molecular targets and modes of action, and confirm the high barrier to resistance observed for the formicamycins. Such information is critical for the development of any natural product as a potential antibiotic.
Planned Impact
The proposed work will generate a range of impacts. We describe who will benefit and how below:
1. INDUSTRY. The techniques we use will be of interest to industry, particularly antibiotic development companies such as Warp Drive BIO and Demuris who use genome mining for antibiotic discovery, and Isomerase Therapeutics who develop new molecules through biosynthetic engineering. We are at the forefront of efforts to use CRISPR/Cas9 genome editing for antibiotic discovery and development in Streptomyces bacteria, in particular with the work we have and will do with S. formicae. To our knowledge no one has used CRISPR/Cas9 editing to the same extent and with the same success in any other Streptomyces strain. Thus, our work will provide a proof of concept for this approach and will also yield new molecules and strains that will be of value to industry. We will disseminate our results through publications and at conferences, including industry focussed meetings, e.g. via the Industrial Biotechnology Alliance (IBA) on the Norwich Research (Hutchings and Wilkinson lead the IBA Anti-infectives theme), the Biotech and Life Science Sector group set up by the New Anglia Local Enterprise Partnership (Hutchings is a member) and through our own industry and knowledge exchange contacts. Hutchings has been Associate Dean for Innovation in Science at UEA since 2013 and Wilkinson is co-Director of the BBSRC Natural Products discovery and Bioengineering Network (NPRONET), and a co-founder of Isomerase Therapeutics, so they are well connected. We will share more widely through social media and press releases.
2. SOCIETY. Impact will be achieved long term by the development of new antibiotics either directly via our work on the fasamycins and formicamycins and indirectly when the techniques we are developing are adopted by others to stimulate early stage discovery. Identifying the molecular target for the formicamycins will allow others to develop alternative chemical classes with activity against this target. Impact will also be achieved through public and policy engagement with our research and education about antibiotics and AMR. Two of our co-supervised PhD students did 3-month internships at Westminster in 2017: Rebecca Devine worked with CMO Dame Sally Davies and Sarah Worsley worked in the Science Policy office. These are useful links and Dame Sally Davies has been highly supportive of our research and public engagement efforts, including a book we published on antibiotics with the Science, Art and Writing Trust (http://www.sawtrust.org/buy-the-books/saw-antibiotics/). We will use these contacts to highlight our work and the work of our colleagues in the UK around AMR. Hutchings and Wilkinson have strong track records in public engagement in schools, through public lectures and at major public science events including exhibits at the Royal Society Summer Science Exhibition 2014, the BBSRC Great British Bioscience Festival 2014, Big Bang Science Fair 2015, Norwich Science Festival 2016 and Latitude Festival 2017. Hutchings won a UEA award in 2015 for his outstanding contribution to public and community engagement and the applicants will both continue to engage widely with the public through all available avenues to talk about their work on antibiotics.
3. UEA and JIC. There are potential economic benefits to UEA and JIC through licensing of materials (strains, constructs, molecules) developed during this project. Intellectual property will be protected and licensed by the Research and Innovation Office at UEA and / or Plant Biotech Ltd at the JIC. Another benefit to our host institutes and the Norwich Research Park will be the publicity gained by our work through communication of results at public engagement events and through the media and social media.
1. INDUSTRY. The techniques we use will be of interest to industry, particularly antibiotic development companies such as Warp Drive BIO and Demuris who use genome mining for antibiotic discovery, and Isomerase Therapeutics who develop new molecules through biosynthetic engineering. We are at the forefront of efforts to use CRISPR/Cas9 genome editing for antibiotic discovery and development in Streptomyces bacteria, in particular with the work we have and will do with S. formicae. To our knowledge no one has used CRISPR/Cas9 editing to the same extent and with the same success in any other Streptomyces strain. Thus, our work will provide a proof of concept for this approach and will also yield new molecules and strains that will be of value to industry. We will disseminate our results through publications and at conferences, including industry focussed meetings, e.g. via the Industrial Biotechnology Alliance (IBA) on the Norwich Research (Hutchings and Wilkinson lead the IBA Anti-infectives theme), the Biotech and Life Science Sector group set up by the New Anglia Local Enterprise Partnership (Hutchings is a member) and through our own industry and knowledge exchange contacts. Hutchings has been Associate Dean for Innovation in Science at UEA since 2013 and Wilkinson is co-Director of the BBSRC Natural Products discovery and Bioengineering Network (NPRONET), and a co-founder of Isomerase Therapeutics, so they are well connected. We will share more widely through social media and press releases.
2. SOCIETY. Impact will be achieved long term by the development of new antibiotics either directly via our work on the fasamycins and formicamycins and indirectly when the techniques we are developing are adopted by others to stimulate early stage discovery. Identifying the molecular target for the formicamycins will allow others to develop alternative chemical classes with activity against this target. Impact will also be achieved through public and policy engagement with our research and education about antibiotics and AMR. Two of our co-supervised PhD students did 3-month internships at Westminster in 2017: Rebecca Devine worked with CMO Dame Sally Davies and Sarah Worsley worked in the Science Policy office. These are useful links and Dame Sally Davies has been highly supportive of our research and public engagement efforts, including a book we published on antibiotics with the Science, Art and Writing Trust (http://www.sawtrust.org/buy-the-books/saw-antibiotics/). We will use these contacts to highlight our work and the work of our colleagues in the UK around AMR. Hutchings and Wilkinson have strong track records in public engagement in schools, through public lectures and at major public science events including exhibits at the Royal Society Summer Science Exhibition 2014, the BBSRC Great British Bioscience Festival 2014, Big Bang Science Fair 2015, Norwich Science Festival 2016 and Latitude Festival 2017. Hutchings won a UEA award in 2015 for his outstanding contribution to public and community engagement and the applicants will both continue to engage widely with the public through all available avenues to talk about their work on antibiotics.
3. UEA and JIC. There are potential economic benefits to UEA and JIC through licensing of materials (strains, constructs, molecules) developed during this project. Intellectual property will be protected and licensed by the Research and Innovation Office at UEA and / or Plant Biotech Ltd at the JIC. Another benefit to our host institutes and the Norwich Research Park will be the publicity gained by our work through communication of results at public engagement events and through the media and social media.
Organisations
Publications
Batey SFD
(2020)
Chemical warfare between fungus-growing ants and their pathogens.
in Current opinion in chemical biology
Devine R
(2021)
Re-wiring the regulation of the formicamycin biosynthetic gene cluster to enable the development of promising antibacterial compounds
in Cell Chemical Biology
Feeney MA
(2022)
ActinoBase: tools and protocols for researchers working on Streptomyces and other filamentous actinobacteria.
in Microbial genomics
McDonald HP
(2023)
Heterologous Expression of the Formicamycin Biosynthetic Gene Cluster Unveils Glycosylated Fasamycin Congeners.
in Journal of natural products
McLean TC
(2019)
Dissolution of the Disparate: Co-ordinate Regulation in Antibiotic Biosynthesis.
in Antibiotics (Basel, Switzerland)
Qin Z
(2019)
A role for antibiotic biosynthesis monooxygenase domain proteins in fidelity control during aromatic polyketide biosynthesis.
in Nature communications
Qin Z
(2020)
Formicamycin biosynthesis involves a unique reductive ring contraction.
in Chemical science
Vikeli E
(2020)
In Situ Activation and Heterologous Production of a Cryptic Lantibiotic from an African Plant Ant-Derived Saccharopolyspora Species.
in Applied and environmental microbiology
Description | We have discovered a new group of antibiotics and found that pathogenic bacteria do not become resistant to them in vitro. We have engineered the genes encoding biosynthesis of these antibiotics so we can make strains that over-produce them and also make new variants. These molecules hare very promising drug candidates |
Exploitation Route | A company could tale the molecules forward for clinical trials. |
Sectors | Healthcare |
Title | Structural determination of fasamycin and formicamycin congeners isolated from regulator mutants of S. formicae |
Description | Structural determination of fasamycin and formicamycin congeners isolated from regulator mutants of S. formicae. See manuscript for details including methodology. |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
URL | https://figshare.com/articles/dataset/Structural_determination_of_fasamycin_and_formicamycin_congene... |
Title | Structure determination of new fasamycin and formicamycin congeners |
Description | Structural elucidation of new fasamycins and formicamycins from de-repressed S. formicae mutants. See manuscript for more information including methodology. |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
URL | https://figshare.com/articles/dataset/Structure_determination_of_new_fasamycin_and_formicamycin_cong... |
Description | Public lecture at Norwich Science Festival 2024 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | I gave a public lecture entitled Antibiotics in Nature and Medicine at the Norwich Science Festival 2024 |
Year(s) Of Engagement Activity | 2024 |